BioSpace News Archive

4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced that interim clinical data from the Phase 1/2 clinical trial of 4D-710 for cystic fibrosis lung disease were presented at the North American Cystic Fibrosis Conference (NACFC).

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that it will present new data from its Phase 1/1b trial of CPI-818, the Company’s ITK inhibitor, at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place in-person and virtually from December 10-13, 2022.

Pacylex, a clinical-stage NMT inhibitor company developing first-in-class therapies for leukemia, lymphoma, and solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for PCLX-001 for the treatment of acute myeloid leukemia (AML).

Ichnos Sciences Inc. announced that four abstracts highlighting data on its pipeline assets have been selected for presentation at the upcoming 64th American Society of Hematology Annual Meeting and Exposition.

American Aires Inc. (CSE: WIFI) (OTCQB: AAIRF) (the “Company” or “Aires”) announces that, further to its previous press releases of May 9, 2022, June 23, 2022, August 2, 2022, August 26, 2022, September 21, 2022 and October 21, 2022,

Salarius Pharmaceuticals, Inc. (NASDAQ: SLRX) today announced that two abstracts related to the company’s compounds have been accepted for presentation at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 10-13, 2022 in New Orleans and virtually.

Kezar Life Sciences, Inc. (Nasdaq: KZR) today announced that it presented the complete data set from the MISSION Phase 2 clinical trial evaluating zetomipzomib, a novel, first-in-class, selective immunoproteasome inhibitor, in active lupus nephritis (LN) at the American Society of Nephrology’s (ASN) Kidney Week 2022 Annual Meeting in Orlando, FL.

Axcella Therapeutics (Nasdaq: AXLA) today announced that it will present data on clinical plasma proteomic biomarkers in patients with NASH at the American Association for the Study of Liver Diseases (AASLD) Annual Meeting being held in Washington, D.C., November 4-8, 2022.

AI Proteins, the biotechnology company using artificial intelligence to design synthetic proteins de novo, announced its public launch and the close of an oversubscribed $18.2 million seed series co-led by Cobro Ventures and Lightchain Capital.

Sumitomo Pharma Oncology, Inc., a clinical-stage company focused on novel cancer therapeutics, today announced preliminary clinical data for investigational agent TP-3654 will be presented at the 64th American Society of Hematology (ASH) Annual Meeting & Exposition, which is being held December 10-13 in New Orleans, Louisiana.